CD7 (CD7 Molecule)

Treatment with topical corticosteroids has provided considerable improvements, showing resolution of lesions. To the best of our knowledge, this is the first case of LyP type E affecting a pediatric patient with lesions confined to the oral mucosa.

P1, N=2, Completed, MEI HENG | Recruiting --> Completed | N=18 --> 2

P=N/A, N=100, Recruiting, Shanghai Children's Medical Center Affiliated to School of Medicine, Shanghai Jiaotong University; Shanghai Children's Medical Center Affiliated to Sc

Compared with non-APL-AML patients, APL patients (PML-RARα (S-type) and PML-RARα (L-type)) exhibit unique immunophenotypic changes. The expression frequencies of CD56, CD2, CD34, and CD200 in leukemia cells are significantly correlated with the OS of APL patients, and the high expression of these indicators before treatment may be an adverse prognostic factor for APL patients.

Despite this scientific and clinical progress, the high cost of developing CAR T cells through the traditional biopharma pathway is limiting late-stage clinical development, necessitating the creation of new business models to commercialize CAR T cells for these small markets. CAR T cells hold great promise for improving outcomes for pediatric patients with cancer, but substantial additional research and clinical development is needed if this promise is to be realized for children afflicted with cancer.

P=N/A, N=28, Not yet recruiting, Donghua Zhang

P1, N=15, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.

These include degraders targeting resistant EGFR, antibodies depleting CD7+ pathogenic lymphocytes, ADAR-based RNA sensors for drug discovery, and quinazoline inhibitors penetrating the brain to block C797X double mutants. Together, these platforms illustrate convergent approaches to dismantle disease drivers at protein, immune, RNA, and signaling levels.

This case highlights the diagnostic challenge of distinguishing rare lymphomas from common infections in tuberculosis-endemic regions and underscores the necessity of early tissue diagnosis with immunophenotyping when faced with unexplained large pleuro-pericardial effusions. Prompt recognition is crucial because T-LBL requires intensive ALL-type therapy, which significantly improves survival compared with conventional lymphoma regimens.

Our data suggest that early administration of IDM may contribute to a rapid resolution of severe or steroid-refractory ICANS after CAR-T cell therapies, which may create opportunities for subsequent treatments in these patients. Larger sample and multicenter clinical trials are warranted to further validate these findings.

A review of published ZMYND11::MBTD1 leukemias (n = 5) found immunophenotypes highly consistent with MNKPL, suggesting prior misclassification. These findings support ZMYND11::MBTD1 as a recurrent lesion in MNKPL and a practical aid to diagnosis and treatment selection.